ArticleObesity surgery2026
Udca Dosage, Duration, and Initiation Timing for Post-metabolic Bariatric Surgery Scholelithiasis Prevention: A Scoping Review.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic Bariatric Surgery (MBS), an effective intervention for severe obesity, elevates the risk of cholelithiasis (CL) due to rapid weight loss and altered biliary metabolism. Ursodeoxycholic acid (UDCA) is increasingly investigated as a prophylactic strategy to mitigate this complication. This scoping review aimed to map and compare UDCA dosage, duration, and initiation timing protocols for CL prevention after MBS. A review was conducted across PubMed/MEDLINE, Web of Science, and Scopus, selecting 10 articles published between 2014 and 2023. The analyzed literature consistently indicates that UDCA prophylaxis significantly reduced CL incidence from 25 to 40% in control groups to 1.4–10.8% in treated groups. Studies commonly reported dosages of 500–600 mg/day for 6 months postoperatively were common, with early initiation being crucial. Efficacy is evident for both Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB), with CL relative risks between 0.13 and 0.36. The evidence demonstrates UDCA safety, efficacy, and cost-effectiveness. Collectively, the literature supports UDCA as an effective and safe prophylactic measure against post-MBS cholelithiasis. The identified heterogeneity in protocols underscores the need for standardization to optimize clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.